Rule: 2-40.007 Prev Up Next
| Rule Title: Rescheduling of a Drug Product in Finished Dosage Formulation That Has Been Approved by the U.S. Food and Drug Administration That Contains Cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) Derived from Cannabis and No More Than 0.1 Percent (w/w) Residual Tetrahydrocannabinols | |||
| Department: | DEPARTMENT OF LEGAL AFFAIRS |
 Add to MyFLRules Favorites |
|
| Division: | Departmental | ||
| Chapter: | SCHEDULING AND RESCHEDULING OF CONTROLLED SUBSTANCES | ||
Latest version of the final adopted rule presented in Florida Administrative Code (FAC):
|
Effective Date: | 2/7/2019 |
| History Notes: | Rulemaking Authority 893.0355 FS. Law Implemented 893.0355 FS. History–New 2-7-19. | |
| References in this version: | No reference(s). |
| Notice / Adopted |
Description | ID | Publish Date |
|
|---|---|---|---|---|
|
Rescheduling of a Drug Product in Finished Dosage Formulation That Has Been Approved by the U.S. Food and Drug Administration That Contains Cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) .... | 21423534 |
Effective: 02/07/2019 |
|
|
|
The proposed rule is intended to reschedule a drug product in finished dosage formulation that has been approved by the Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1, .... | 21253687 |
12/13/2018 Vol. 44/241 |
|
|
|
The proposed rule development is intended to reschedule a drug product in finished dosage formulation that has been approved by the Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1, .... | 21194711 |
11/27/2018 Vol. 44/229 |
|